259
Participants
Start Date
June 30, 2008
Primary Completion Date
April 30, 2011
Study Completion Date
September 30, 2015
Pomalidomide
1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
Dexamethasone
oral dexamethasone
Aspirin
As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
Mt. Sinai Hospital, New York
Roswell Park Cancer Institute Department of Medicine, Buffalo
University of Pittsburgh, Pittsburgh
Winship Cancer Institute of Emory University, Atlanta
Moffitt Cancer Center, Tampa
University of Michigan Comprehensive Cancer CenterDivision of Hematology/Oncology, Ann Arbor
Mayo Clinic - Arizona, Rochester
Washington University School of Medicine, St Louis
Colorado Blood Cancer Institute, Denver
Mayo Clinic Arizona, Scottsdale
Mass General Hospital, Boston
Dana-Farber Cancer Institute, Boston
The Cancer Center at Hackensack University Medical Center, Hackensack
Ohio State University Arthur G. James Cancer Hospital, Columbus
Tom Baker Cancer Center, Calgary
Cross Cancer Institute, Edmonton
Vancouver General Hospital, Vancouver
Princess Margaret Hospital and University of Toronto, Toronto
Royal Victoria Hosptial, Montreal
Lead Sponsor
Celgene Corporation
INDUSTRY